In 2017, Danielle Lynch joined Phreesia to lead business development for its agency partners. Her abilities were quickly recognized as Lynch was promoted to VP of client experience, and now leads both sales and content strategy for the company. Her leadership in refining Phreesia’s go-to-market model and its approach to developing new partnerships has helped the company increase revenue, grow its partnerships and improve its product offerings and capabilities.
Lynch began her healthcare marketing career at Cline Davis & Mann in 2006, where she worked on Pfizer’s Lipitor, the agency’s largest account. From there, she was selected to join Cline Davis & Mann’s spin-off agency, Lab9, which was created to manage Genentech’s Rituxan RA business. Between 2007 and 2010, Lynch worked with a wide range of clients and led multiple launches.
Following Cline Davis & Mann’s 2010 merger with AgencyRx, Lynch was assigned to work on the launch of Embeda, a pain medicine, by leading the brand’s sales-training efforts. From there, she joined the team working on Multaq, Sanofi’s cardiovascular drug, where she worked on digital promotion and revamping the campaign’s message.
In 2011, Lynch returned to AgencyRx to lead the launch of Pomalyst, Celgene’s multiple myeloma therapy. Over the next five years, she supervised Celgene’s multiple myeloma business in addition to managing the manufacturer’s $1 billion hematology franchise.
From the May 01, 2020 Issue of MM+M - Medical Marketing and Media
